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1. Introduction 
Substrate analogs bearing ionizable nitro groups in 
place of carboxylate groups have proven to be inter- 
esting inhibitors of enzymes [l-5]. For instance, 
2nitropropane (which is isoelectronic with the alanine 
zwitterlon) and the toxic antibiotic 3-~tropropionate 
(which is isoelectronic with succinate) irreversibly 
inactivate the flavin-dependent enzymes D-amino acid 
oxidase and succinate dehydrogenase, respectively, in 
m~chanist~~~ly distinct ‘suicide’ reactions [3]_ The 
nitronates obtained upon deprotonation of aliphatic 
nitro compounds generally bind well to enzymes 
which act on corresponding carboxylic compounds. 
In fact, in special cases in which the nitronates func- 
tion as ‘transition-state analogs’, they bind by orders 
of magnitude more tightly than the carboxylic sub- 
strates [4,5]. 
Here, we report that several pyridoxal 5’-phos- 
phate-dependent enzymes are subject to inactivation 
by a nitro analog of their substrate ~utamate. 
Although 5-nitro-L-norvaline (fig.2) sterically resem- 
bles L-2-aminoadipic acid somewhat more closely 
than it resembles L-glutamic acid, the lower homolog 
of S-~tro-L-no~ali~e is an unsown and probably 
unstable [6] compound. However, the nitronate form 
of 5nitro-L-norvaline exhibits nearly the same intra- 
molecular charge separation as occurs in the L-gluta- 
mate anionic species; and 5-nitro-L-norv~ine is accept- 
ed into the active sites of alanine aminotransferase 
(EC 2.6.1.2), aspartate aminotransferase (EC 2.61 .l), 
and 4-aminobutyrate aminotransferase (EC 2.6.1.19), 
all of which act on L-glutamate. 
2. Materials and methods 
5-Nitro-L-norvaline (a gift from Dr W. Keller- 
QsevierfNorth-Holland Biomedical Press 
Schierlein) [7] and 3-nitro-D,L-alanine (a gift from 
Dr D. J. T. Porter) ]5] were synthesized as described. 
4-Aminobutyrate arninotransferase and succinate 
semialdehyde dehydrogenase were from Pseudomonas 
fluorescens. The other aminotransferases as well as 
lactate and malate dehydrogenases were the cytosolic 
enzymes from porcine heart. The enzymes and cofac- 
tors were products of the Sigma (St Louis MO). After 
dialysis against phosphate buffer, the aminotransfer- 
ases were not stimulated by additional pyridoxal 5’- 
phosphate. 
The aminotransferase activities were assayed by 
the dehydrogenase-coupled method [S]. One unit of 
aminotransferase was taken to generate 1 .O pmol 
product~min from 50 mM substrate (L-alanine, L-as- 
partate, or 4-aminobutyrate) in the presence of 10 
mM 2-oxoglutarate, I .O mM EDTA, and 100 mM 
Tris-HCI at pH 8.0 and 25°C. 
3. Results 
Representative time courses for the inactivation of 
aminotransferases by 5-nitro-L-norvaline are shown in 
fig.1. The itlactivation reproducibly does not proceed 
in a first-order exponential manner. The inactivation 
does not proceed to completion at low S-nitro-C 
norvaline concentrations, and the incompleteness of 
the inactivation is not mitigated by the presence of 
1 .O mM 2-oxoglutarate. The incompleteness is thus 
not secondary to the conversion of the enzymes to 
their pyridoxamino states. One reason [8] that the 
loss of activity is not a simple Iirst-order function of 
time is that the inactivation is, in part, slowly revers- 
ible. After nearly complete inactivation of aspartate 
aminotransferase by 5nitro-L-norvaline, 96% of the 
activity is recovered within 8.0 h of dialysis against 
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Fig. I. Inactivation of aminotransferase by 5~nitro-L-norvaline. 
The indicated enzymes (-1 unit/ml) were incubated with 
S-ni~ro-L-no~aiine (5 ,O, 20 and 100 PM) in 100 mM potassium 
phosphate buffer at pH 7.4 and 25”C, and small aliquots of 
the reaction misture were periodically diluted loo-fold and 
tested for transaminase activity. Inactivation does not require 
the presence of an oxoacid substrate and can be completdy 
prevented by the presence of 50 mM L-glutamate, 
10 mM potassium phosphate buffer at pH 7.4 and 4°C. 
However, only 36% and 8%, respectively, of the alanine 
and 4-aminobutyrate aminotransferase activities are 
recovered, and these yields are not increased by treat- 
ment with 10 mM D,L-dit~othreitol and 0.1 mM 
pyridoxal 5’-phosphate during more-prolonged diai- 
ysis. Samples of the enzymes not treated with Witro- 
L-norvaline retain over 90% of their activity when 
subjected to dialysis for 24 h. The ~neti~~ly com- 
plex inactivation thus has both slowly reversible and 
irreversible features, and kinetic analysis is further 
complicated by the observation that some totally 
irreversible active-site directed inactivators of these 
enzymes are known to react in a markedly biphasic 
manner [9]. 
The inactivation is not a non-specific effect of the 
nitro group. Thus, neither 10 mM nitroeth~e nor its 
potassium salt inactivate the enzymes under the con- 
ditions in fig.1. The enzymes are very slowly and irre- 
versibly inactivated by 10 mM 3-nitro-D,L-alanine, 
but that reaction probably proceeds by a different 
mechanism analogous to that of the suicide substrate 
3-fluoroalanine [ I]. 
4. Discussion 
The anticipated reaction mechanism which prompt- 
ed this investigation is outlined in fig.2. The ketimine 
adduct of 5-niiro-L-norv~~ne with pyridoxal S-phos- 
phate is expected to cyclize in a reaction similar to 
the aldol condensation. Model reactions for the pro- 
posed cyclization include the slow reactions of pyri- 
doxal5’-phosphate with dopa or with histidine to 
afford &membered cyclic adducts [ 10,111. The cycli- 
zation of 5nitro-L-norvaline is probably slowly revers- 
ible, but the initially-generated &membered structure 
shown in fig.2 may irreversibly eliminate inorganic 
nitrite because of the carbanion-stabilizing pyridinium 
substituent. Other derivatives of 1-amino-4-nitro- 
butane in addition to 5nitro-L-norvaline ought to 
sirn~arly inactivate those pyridoxal S’-phosphate- 
dependent enzymes for which the substrates are 
resembled. Similarly, derivatives of l-arllino-3-l~itro- 
propane ought to inactivate such enzymes by forming 
S-n~embered cyclic adducts with the coenzyme. Thus, 
advances in the organic synthesis of nitroalkylamines 
may permit their use as selective ina~tivators of phar- 
macologicahy interesting targets [I ] including 4-ami- 
Pig.2. Probable mechanism by which pyridoxal 5’-phosphate- 
dependent enzymes are inactivated by !Gnitro-L-norvaiine. A
metastable 6-membered cyclic adduct is generated in a slowly 
reversible reaction, but the adduct may irreversibly eliminate 
inorganic nitrite [ 21 because of the influence of the pyridinium 
ring. 
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nobutyrate am~otransferase, Ldopa decarboxylase, 
L-histidine decarboxylase, L-serine transhydroxy- 
methylase, the microbial enzymes acting on D-amino 
acids, and the amine oxidases possessing pyridoxal- 
like prosthetic groups. 
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